Akero Therapeutics (AKRO) said Monday it has started an underwritten public offering of $300 million of shares, with J.P. Morgan, Morgan Stanley and Jefferies as book-running managers.
The underwriters will be given a 30-day option to buy up to an additional $45 million of shares, the clinical-stage company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。